↓ Skip to main content

The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome

Overview of attention for article published in BMC Musculoskeletal Disorders, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

news
1 news outlet
twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome
Published in
BMC Musculoskeletal Disorders, January 2014
DOI 10.1186/1471-2474-15-21
Pubmed ID
Authors

Sarah Brown, Nuria Navarro Coy, Costantino Pitzalis, Paul Emery, Sue Pavitt, Janine Gray, Claire Hulme, Frances Hall, Robert Busch, Pete Smith, Luke Dawson, Michele Bombardieri, Ng Wan-fai, Colin Pease, Elizabeth Price, Nurhan Sutcliffe, Clodagh Woods, Sharon Ruddock, Colin Everett, Catherine Reynolds, Emma Skinner, Ana Poveda-Gallego, John Rout, Iain Macleod, Saaeha Rauz, Simon Bowman

Abstract

Primary Sjögren's Syndrome (PSS) mainly affects women (9:1 female:male ratio) and is one of the commonest autoimmune diseases with a prevalence of 0.1 - 0.6% of adult women. For patients with PSS there is currently no effective therapy that can alter the progression of the disease. The aim of the TRACTISS study is to establish whether in patients with PSS, treatment with rituximab improves clinical outcomes.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 1 <1%
Netherlands 1 <1%
Unknown 103 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 21%
Researcher 17 16%
Student > Master 14 13%
Student > Bachelor 10 10%
Student > Doctoral Student 9 9%
Other 18 17%
Unknown 15 14%
Readers by discipline Count As %
Medicine and Dentistry 52 50%
Immunology and Microbiology 5 5%
Biochemistry, Genetics and Molecular Biology 5 5%
Economics, Econometrics and Finance 5 5%
Agricultural and Biological Sciences 5 5%
Other 11 10%
Unknown 22 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2016.
All research outputs
#1,774,305
of 15,917,790 outputs
Outputs from BMC Musculoskeletal Disorders
#389
of 3,079 outputs
Outputs of similar age
#28,568
of 256,319 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#1
of 1 outputs
Altmetric has tracked 15,917,790 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,079 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 256,319 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them